Abstract
Bisphosphonates (BPs) are the most widely used and effective anti-resorptive agents for the treatment of diseases in which there is an increase in osteoclastic resorption, including post-menopausal osteoporosis, Paget’s disease, and tumor-associated osteolysis. BPs are chemical analogs of inorganic pyrophosphate (PPi) and, although they share many pharmacological features with PPi, there are important biochemical differences, particularly in the way in which they bind to bone mineral and their effect on bone resorption. BPs are preferentially incorporated into sites of active bone remodeling, as commonly occurs in conditions characterized by accelerated skeletal turnover. These drugs can be grouped in three different classes: first-generation, non-nitrogen containing BPs (e.g., clodronate and etidronate), second-generation nitrogen-containing BPs (N-BPs, e.g., pamidronate and alendronate) and third-generation N-BPs (e.g., ibandronate and zoledronate) and the phosphonocarboxylate analogue 3-PEHPC. BPs have several common properties, including poor intestinal absorption, high affinity for bone mineral, inhibitory effects on osteoclastic bone resorption, prolonged bone retention, and elimination in the urine. They are generally well tolerated, even if side effects have been described.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanism of action of bisphoshonate. Cancer 88:2961–2978
Roger MJ (2003) New insights into the molecular mechanism of action of bisphosphonates. Curr Pharm Des 9:2643–2658
Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119:S150–S162
Russell RG (2006) Bisphosphonates: from bench to bedside. Ann NY Acad Sci 1068:367–401
Chapurlat RD, Delmas PD (2006) Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2:211–219
Alakangas A, Selander K, Mulari M et al (2002) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40–47
Roelofs AJ, Thompson K, Gordon S et al (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s–6230s
Coxon FP, Ebetino FH, Mules EH et al (2005) Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37:349–358
Coxon FP, Helfrich MH, Larijani B et al (2001) Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276:48213–48222
Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic, San Diego
Barrett J, Worth E, Bauss F et al (2004) Ibandronate: a clinical pharmacological and pharmacoknetic update. J Clin Pharmacol 44:951–965
Cremers SCLM, Pillai G, Papapoulos SE (2005) Pharmacokinetics-pharmacodynamics of bisphosphonates. Clin Pharmacokinet 44:551–570
Russel RGG (2007) Determinants of structure-function relationships among bisphosphonates. Bone 40:S21–S25
Riis BJ, Ise J, von Stein T et al (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871–1878
Tankó LB, Mouritzen U, Lehmann HJ et al (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687–693
Liamis G, Milionis HJ, Elisaf M (2009) A review of drug-induced hypocalcemia. Bone Miner Metab 27:635–642
Levine MA, Grootendorst P (2000) Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy. Pharmacoepidemiol Drug Saf 9:367–370
Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135:219–222
French DD, Margo CE (2008) Postmarketing surveillance of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28:889–893
Maalouf NM, Heller HJ, Odvina CV et al (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48–53
Odvina CV, Zerwekh JE, Rao ES et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301
Visekruna M, Wilson D, McKienan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952
US Food and Drug Administration (2008) Information for healthcare professionals: bisphosphonates (marketed as Actonel, Actonel Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax D, Reclast, Skelid, and Zometa), January 7, 2008. http://www.fda.gov/CDER/drug/InfoSheets/HCP/bisphosphonatesHCP.htm. Accessed 6 June 2008
Hewitt RE, Lissina A, Green AE et al (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111
Edwards BJ, Gounder M, McKoy JM et al (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172
King AE, Umland EM (2008) Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28:667–677
Ruggiero S, Gralow J, Marx RE (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7–14
Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410
Kontoleon P, Ilias I, Stavropoulos PG et al (2000) Urticaria after administration of alendronate. Acta Derm Venereol 80:398
Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89–90
Cummings SR, Schwartz AV (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895–1896
Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365–366
Ten Dam MA, Hilbrands LB, Wetzels JF (2010) Nephrotic syndrome induced by pamidronate. Med Oncol Sep 24 (Epub ahead of print)
Weide R, Koppler H, Antras L et al (2010) Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 6:31–35
Acknowledgment
The authors thank Dr. Filippo Zagarella for his skilled technical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Milan
About this chapter
Cite this chapter
De Sarro, A., Minutoli, L. (2012). Pharmacology: Mechanism of Action of Bisphosphonates. In: De Ponte, F. (eds) Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-2083-2_2
Download citation
DOI: https://doi.org/10.1007/978-88-470-2083-2_2
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2082-5
Online ISBN: 978-88-470-2083-2
eBook Packages: MedicineMedicine (R0)